IGC

IGC Pharma, Inc. (IGC) SWOT Analysis Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Negative net debt and low leverage reduce refinancing pressure versus more indebted peers, but the balance sheet does not yet create a durable competitive advantage.

The very negative cash conversion cycle indicates supplier-funded working capital, which can support liquidity relative to peers with cash-consuming operations.

Low debt-to-equity suggests limited fixed-charge burden versus leveraged micro-cap peers, helping preserve optionality during periods of weak operating performance.

Weaknesses

Score:

Negative ROIC shows capital deployment is destroying value versus peers that at least earn positive returns, signaling structurally weak economic productivity.

Current and quick ratios below 1.0 indicate tight near-term liquidity versus better-capitalized peers, increasing dependence on external funding.

The absence of reported operating and gross margins limits evidence of durable pricing power, leaving the company structurally weaker than profitable peers.

Opportunities

Score:

If management improves working-capital discipline, the already negative cash conversion cycle could further support liquidity versus peers with slower cash collection.

A low leverage base provides room to simplify the capital structure relative to indebted peers, which could improve financial flexibility if operating performance stabilizes.

Any future margin disclosure improvement would matter because peers with visible profitability typically command stronger positioning, but current data do not confirm that path.

Threats

Score:

Persistently negative ROIC raises the risk of continued value destruction versus peers, which can erode investor confidence and constrain strategic flexibility.

Sub-1.0 liquidity ratios leave the company more exposed than peers to working-capital shocks, supplier tightening, or delayed receivables.

Because profitability metrics are not disclosed, peers with clearer earnings power may continue to outcompete IGC for capital and market credibility.

Overall Score

Score:

IGC’s structural positioning versus peers is weak overall because low leverage is outweighed by negative returns on capital, thin liquidity, and limited evidence of durable profitability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on IGC Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →